GET DAILY SIGNALSCellectis (CLLS) Q3 2026 Earnings: Watching for Shifts in Losses and Revenue
Key Takeaways
- Cellectis S.A. (CLLS) is expected to report its third-quarter 2026 results after the market close on November 13, 2026.
- Analysts, on average, project a net loss of $0.18 per share, a sharp reversal from the $0.01 per-share profit posted in the same quarter last year.
- Consensus revenue is forecast near $15.61 million, down significantly from the $37.16 million reported in Q3 2025.
- In its most recent quarter, Cellectis beat earnings-per-share (EPS) estimates while missing on the revenue line, a pattern investors will watch closely.
- Key themes heading into the print include research and development (R&D) spending, cash runway, and clinical progress for its off-the-shelf CAR-T (chimeric antigen receptor T-cell) candidates.
- For more detail on this ticker's Major News, Today's Price Move, Price Targets, and Forecast, explore these dedicated pages.
- Discover automated trading ideas by exploring Trending AI Robots.
Earnings Context and Why It Matters
Cellectis is a clinical-stage biotechnology company focused on gene editing and allogeneic, or "off-the-shelf," CAR-T cell therapies for cancer. Because its products are not yet commercialized, quarterly results often swing sharply based on collaboration revenue, milestone payments, and operating costs rather than product sales. That makes the earnings release a window into the company's spending discipline and cash position. For investors, the report matters less for headline revenue and more for signals about clinical progress, funding, and whether management can extend its financial runway as development costs continue. Prior quarters have shown meaningful revenue volatility tied to partnerships, adding to the importance of guidance and commentary alongside the headline numbers. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Earnings Expectations
Wall Street consensus calls for Cellectis to report a net loss of $0.18 per share for the third quarter of 2026, according to data compiled by MarketBeat. That compares with earnings of $0.01 per share in the year-ago period. On the top line, analysts expect revenue of approximately $15.61 million, a sharp decline from $37.16 million in Q3 2025.
The company's recent reporting history has been uneven. In its most recent quarter, ended June 30, 2026, Cellectis posted a loss of $0.22 per share, narrower than the $0.26 consensus loss, while revenue of roughly $6.90 million fell short of expectations. Cellectis has beaten consensus EPS estimates in three of its last eight quarters, underscoring the volatility that often accompanies milestone-driven biotech revenue. Heading into this report, investors will be watching not only the headline EPS and revenue figures but also R&D expenses, cash and cash equivalents, and any updates to pipeline timelines. From what I see, using Tickeron’s AI Trend Prediction Engine helped highlight some of the momentum patterns in similar names ahead of the release.
Market Reaction and Investor Sentiment
Sentiment heading into the report appears cautious, reflecting the expected year-over-year decline in revenue and the return to a net loss. Cellectis has a history of sharp post-earnings moves, in part because milestone-heavy revenue makes results difficult to forecast. A beat or miss on the top line can matter as much as the EPS figure for a pre-revenue biotech. Key risk factors include the pace of cash burn, potential dilution from financing activities, and any setbacks or delays in clinical programs. Conversely, positive pipeline updates, new collaboration revenue, or disciplined expense management could support the stock. Investors should be prepared for above-average volatility around the announcement given the company's relatively small market capitalization and clinical-stage profile.
Forward Outlook and Key Factors to Monitor
Following the earnings report, investors will likely focus on several forward-looking items. First, cash runway remains a central concern. As a clinical-stage company, Cellectis relies on existing cash and partnership funding to advance its pipeline, so commentary on the balance sheet and any financing plans will be closely scrutinized.
Second, R&D expense trends will matter. The company's spending on clinical trials and manufacturing is a key driver of its losses, and any indication of slowing or accelerating costs can shape expectations for future quarters.
Third, pipeline progress is critical. Updates on its allogeneic CAR-T programs, including enrollment, regulatory interactions, and data readouts, are likely to carry more long-term weight than any single quarter's financials. Investors should also watch for changes in collaboration agreements, which have historically driven large swings in reported revenue.
Finally, broader sentiment toward the biotechnology sector and gene-editing companies may influence how the stock trades after the release, independent of the company's own results. I'm watching this closely as those details often provide the clearest signals for what comes next.
Using AI Tools in Biotech Research
In my own process, I turn to Tickeron’s AI Screener to quickly filter biotech names by fundamentals, patterns, and AI signals. It helps surface comparable ideas and monitor shifts without spending hours on manual reviews. This approach keeps the focus on data-driven comparisons while tracking names like CLLS in a structured way.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
CLLS's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for CLLS turned positive on October 05, 2026. Looking at past instances where CLLS's MACD turned positive, the stock continued to rise in 41 of 46 cases over the following month. The odds of a continued upward trend are 89%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where CLLS's RSI Oscillator exited the oversold zone, 24 of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.
The Momentum Indicator moved above the 0 level on October 28, 2026. You may want to consider a long position or call options on CLLS as a result. In 63 of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 72%.
Following a +12.50% 3-day Advance, the price is estimated to grow further. Considering data from situations where CLLS advanced for three days, in 170 of 214 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
CLLS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 45 of 48 cases where CLLS's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CLLS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Aroon Indicator for CLLS entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 61 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.624) is normal, around the industry mean (3.482). P/E Ratio (-1.672) is within average values for comparable stocks, (-1.183). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (2.441) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 91 (best 1 - 100 worst), indicating slightly worse than average price growth. CLLS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CLLS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a genome engineering company of pre-engineered products for pharmaceutical industry, cell therapies, seed companies, and laboratory researchers
Industry Biotechnology
Advertisement